A phase II, open-label, non-randomized, pilot study assessing the safety, toxicity, and progression free survival of advanced stage ovarian carcinoma patients who underwent treatment with paclitaxel, carboplatin and metformin. An estimated 30 patients will be required for this study.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female Gender
Age greater than 18 years
Advanced stage epithelial ovarian, fallopian tube, or primary peritoneal cancer
Adequate bone marrow function
ECOG performance score of 2 or greater
Patients must be able to swallow oral medication.
You may not be if
Subjects must NOT be taking metformin or have been on metformin in the past 6 months.
Subjects with a diagnosis of epithelial ovarian, fallopian tube or peritoneal cancers of low malignant potential (borderline carcinomas)
Subjects with concomitant malignancy or a previous malignancy within the past three years, melanoma skin cancer excepted
Clareo Health | Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
